Open-label Extension Study of Brazikumab in Ulcerative Colitis
Status:
Enrolling by invitation
Trial end date:
2025-05-19
Target enrollment:
Participant gender:
Summary
The purpose of this OLE Study D5272C00002 (Legacy #3151-202-008) is to permit participants
who previously enrolled in the double-blind Study D5272C00001 (Legacy #3151-201-008) to
receive brazikumab, allowing for long-term observation of safety in these participants
treated with brazikumab. There are no formal hypotheses to be tested. Safety data obtained in
this study will be included in regulatory product submissions as appropriate.